Vivani Medical manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence. It creates a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa. Through dedication and innovation, Second Sight's mission is to develop, manufacture, and market implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight Medical Products located in Sylmar, California, and was founded in 1998.

Cortigent, Inc. engages in developing targeted neurostimulation systems to help patients recover critical body functions. The company was founded in November 2022 and is headquartered in Valencia, CA.

Doheny Eye Institute is an American private company located in Los Angeles, CA. The firm provides eye care related research and education programs. Marissa Goldberg is currently the CEO of the company.\nThe company says this about itself: For more than 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinician-scientists and researchers are changing how people see �� and also how they think about the future of vision. Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best patient care, vision research, and education. This affiliation combines the strength, reputation, and distinction of two of the nation's top eye institutions to advance vision research, education, and patient care in California.

Shenzhen Silicon Bionics Technology Co., Ltd, established on 2015-04-29, Business scope includes general business items:electronic product,Electronic Component,chip,Technical development of computer hardware and software and peripheral auxiliary materials and related technical consultation;Invest in business(Specific projects will be reported separately);Investment in medical projects(Specific projects will be reported separately);Domestic Trade,Import and export of goods and technology.(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:Class I medical device,communication equipment,Assembly of Electronics;Class II,Research and development of three types of medical devices,production and sales.

Pixium Vision is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that for blind people could ultimately provide vision approaching that of a normal healthy Pixium's first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2. Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium is backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos.

Optobionics Corp. develops artificial retina and related devices to restore vision for individuals afflicted with retinitis pigmentosa, age-related macular degeneration, and other outer retinal diseases that can lead to blindness. It was founded by Alan Y. Chow and Vincent Y. Chow in 1990. The company is headquartered in Naperville, IL.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.

Nano Retina, a joint venture of Zyvex Labs (www.zyvexlabs.com), and Rainbow Medical (www.rainbowmedical.co.il), is developing Bio-Retina, a bionic retina designed to restore sight to those suffering from retinal degenerative diseases. Bio-Retina incorporates various nano-size components in one tiny, flat implant, approximating the size of a child’s fingernail bed. Its simple 30-minute implant procedure requires local anesthesia, a small incision and “gluing” of the device to the damaged retina. Return of sight is anticipated to be instantaneous: 20/200 with the first generation and 20/20 with the second generation product, enabling persons who have undergone the procedure to watch TV and identify faces. Recovery time is estimated at up to one week.

Nidek Co. Ltd. develops ophthalmic surgical and diagnostic equipment for the optical and eye care industries. It offers ophthalmic surgical devices, examination and diagnostic devices, electronic medical record and practice management medical filing systems, intra-ocular lenses and dermatological surgical lasers. The company was founded by Hideo Ozawa in July 1971 and is headquartered in Gamagori, Japan.

Shamir Optical Industry Ltd. engages in the development and manufacture of progressive lenses (multifocal lenses), sharp focus contact lenses, and molds. The company It was founded in 1972 and is headquartered in Shamir, Israel.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Hangzhou Nurotron Biotechnology Co., Ltd., (诺尔康神经电子科技) is a high-tech enterprise providing nerve electronic products. The company is mainly involved in the R&D of multipath manual electrical cochlea systems, nationalization and clinical application of auditory brainstem implant equipment, strategy and technology enhancement of home-grown manual cochlea, and more. The company’s headquarters and production base are located in Hangzhou, China, and its R&D center is located in California, USA.

Maculaser Oy is a company headquartered in Helsinki, Finland. The firm operates medical technology company on blindness by targeting major retinal disease. It was founded in 2020 by Ossi Kaikkonen, Jani Marko Petteri Tirronen and Teemu Tapio Turunen. Jani Marko Petteri Tirronen has been the CEO since that date.

IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception. The company was founded in 2002 and has 30 employees.\nThe company has a process oriented quality management system in accordance with ISO 13485.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Engages in the development and domestic implantable medical devices

Johnson & Johnson Vision Care is committed to creating life-long solutions to vision care needs. Since the ACUVUE Brand made its debut in 1987 as the world’s first disposable soft contact lens, the company has repeatedly brought quality, scientific and innovative advancements to the industry. Headquartered in Jacksonville, Florida, the company has some 3,000 employees worldwide.

Matsushita Electronics Corp. develops and manufactures electronic products. Its products include plasma TVs, DVD players, and digital cameras. It is a subsidiary of Matsushita Electric Industrial Co. Ltd. The company is headquartered in Osaka, Japan.